Vical VICL Swine Flu Vaccine Shows Promise

September 10, 2009 - Shares of Vical Incorporated (VICL) are set to open higher as the company has come out with some promising Swine Flu Vaccine Data today. As for VICL stock, its set to open Up 13% to $5.75

Vical Pandemic Influenza Vaccine Demonstrates Cross-reactivity Against California, Texas and Mexico H1N1 Strains

Vical Incorporated (Nasdaq:VICL) announced today that the company's DNA vaccine against A/H1N1 pandemic influenza (swine flu) has demonstrated robust immune responses in 100% of vaccinated animals against virus strains isolated from recent outbreaks in three distinct geographic locations -- California, Texas and Mexico.

Vical's plasmid DNA vaccine contains the H1 hemagglutinin gene sequence provided by the U.S. Centers for Disease Control and Prevention (CDC) for the swine-origin A/California/04/09 pandemic influenza virus, and after two doses produced immune responses well above the accepted protection threshold in 100% of vaccinated mice and rabbits using HI assays against the swine-origin A/California/07/09 x-179a, A/Texas/15/09 and A/Mexico/4108/09 influenza viruses. Hemagglutination inhibition (HI) titers were well above the protection threshold of 40, ranging from 320 to 2,560 in mice, and from 640 to 2,560 in rabbits against the California strain. Results against the Texas and Mexico strains were essentially equivalent, ranging from 640 to 2,560 in both mice and rabbits. Vical's vaccine would also be expected to provide similar robust immune responses against other swine-origin A/H1N1 influenza virus subtypes, supporting selection of a single A/H1N1 virus strain as the basis for the vaccine. Full Article

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free

Vical VICL Swine Flu H1N1 Vaccine Promising

Shares of Vical Inc. (VICL) are surging this morning ( 6/30/09 ) because they company is out with some promising data for their swine flu vaccine. Discuss VICL

Discuss Stocks - http://stockstobuy.org

Vical Inc. ( VICL ) Stock News - June 30, 2009

Vical H1 Influenza Vaccine Delivers Robust Preclinical Results With 100% Response

June 30, 2009 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company's vaccine against A/H1N1 pandemic influenza (swine flu) produced robust immune responses well above the accepted protection threshold in 100% of vaccinated mice and rabbits after a standard two-dose vaccine regimen. In addition, at least 75% of vaccinated animals achieved or exceeded the protection threshold after a single dose of vaccine. The company is ready to advance directly to large-scale cGMP manufacturing of the vaccine for human clinical trials, subject to securing external funding for this program.

"Our DNA vaccine technology offers an innovative approach to dealing with pandemics," said Vijay B. Samant, President and Chief Executive Officer of Vical. "The speed of our platform both in development and manufacturing was demonstrated by our rapid completion of vaccine production and successful immunogenicity testing in animals while conventional vaccine manufacturers are still working toward production of their initial supply of H1 vaccine. We are encouraged by these compelling data with our Vaxfectin(r)-formulated DNA vaccine and we look forward to advancing to human clinical trials as soon as possible."

Full Article

For More Stock Market Updates, visit , http://daytradingstockblog.blogspot.com/ or Subscribe for FREE